Kiniksa Pharmaceuticals International, plc 8-K — AI Bull & Bear Analysis

The filing of this deed of waiver represents a critical pivot in Kiniksa's corporate governance, attempting to balance the influence of a major institutional investor with the requirements of public market compliance. While the move superficially cleans up the cap table and removes immediate regulatory threats, it exposes the high degree of concentration in the company's ownership. The ultimate impact will depend on whether this agreement fosters a collaborative relationship with Baker Brothers or creates a bottleneck for future strategic pivots and capital infusions.